Clinical Trial UCI-15-99


Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma

Principal Investigator

Daniela Bota


Learn More

For more information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email